Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In this paper, we systematically review the literature on papillary thyroid carcinoma (PTC) metastasis to the mandible. This is a rare oc-currence, especially in young, asymptomatic patients. We propose appropriate surgical and adjuvant therapy guidelines based on our findings. A systematic PubMed search (up to July 2023) identified 10 eligible cases of papillary or follicular thyroid carcinoma with metastasis to the mandible. Studies of patients with different histologic types or without confirmed distant metastasis were excluded. A rare case of PTC metastasizing to the mandible in a young male highlights an unusual presentation. Surgical treatment of both primary and metastatic sites, along with aggressive adjuvant therapy after surgery, had a positive impact on survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041427 | PMC |
| http://dx.doi.org/10.5125/jkaoms.2025.51.2.73 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis and management of thyroid nodule.
Curr Opin Endocrinol Diabetes Obes
October 2025
Department of Surgery, American Mission Hospital, Manama, Bahrain.
Purpose Of Review: To review the current medical evidence in the diagnosis and management of thyroid nodules.
Recent Findings: The widespread use of imaging modalities in recent years has led to frequent discovery of incidental thyroid nodules. These nodules are mostly benign (over 90%), hence precise insight in evaluating nodules of concern and following up other nodules is important to avoid unnecessary surgeries and its complications.
FTOregulated mA modification of primiR139 represses papillary thyroid carcinoma metastasis.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Information Network Center, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: Increasing detection of low-risk papillary thyroid carcinoma (PTC) is associated with overdiagnosis and overtreatment. N6-methyladenosine (mA)-mediated microRNA (miRNA) dysregulation plays a critical role in tumor metastasis and progression. However, the functional role of mA-miRNAs in PTC remains unclear.
View Article and Find Full Text PDFEfficacy and safety of US-guided thermal ablation for elderly patients with solitary papillary thyroid carcinoma: a multicenter preliminary study.
Int J Hyperthermia
December 2025
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Objective: This study aimed to evaluate the efficacy and safety of US-guided thermal ablation (TA) for solitary papillary thyroid carcinoma (PTC) in elderly patients.
Materials And Methods: This retrospective study included 91 elderly patients with solitary PTC who were treated with TA. The primary outcome was disease progression.
Second Primary Papillary Thyroid Carcinoma: Insights From Competing Risk Analysis and Post-RAIT.
Clin Endocrinol (Oxf)
September 2025
Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Improved cancer survival rates have highlighted second primary malignancies (SPMs), with the thyroid gland being one of the most common organs developing SPMs in cancer survivors. Second primary papillary thyroid carcinoma (2-PTC) is the predominant type, yet it remains poorly understood. This study aims to delineate the clinicopathological features and survival outcomes of 2-PTC and assess the efficacy of postoperative radioactive iodine therapy (post-RAIT) in reducing mortality risks in intermediate-risk 2-PTC patients.
View Article and Find Full Text PDFPembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68Ga-FAPi PET/CT.
Clin Nucl Med
September 2025
Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events.
View Article and Find Full Text PDF